Compare Cadila Healthcare with Aventis Pharma - Equitymaster

Helping You Build Wealth With Honest Research
Since 1996. Try Now

  • MyStocks

MEMBER'S LOGINX

     
Login Failure
   
     
   
     
 
 
 
(Please do not use this option on a public machine)
 
     
 
 
 
  Sign Up | Forgot Password?  

CADILA HEALTHCARE vs SANOFI INDIA - Comparison Results

CADILA HEALTHCARE     Change

Cadila Healthcare is one of the leading players in the Indian pharma market having a presence in both the domestic and international markets. In the international markets, the company had adopted the strategy of competing directly in the generics mar... More

SANOFI INDIA 
   Change

Sanofi India (the erstwhile Aventis Pharma), the 60% subsidiary of Sanofi-Aventis SA, France, is one of the largest pharma MNCs in India with a turnover of over Rs 13.2 bn in CY11. Domestic sales constituted 81% of total sales in CY11 and exports con... More

DO YOU LIKE THESE REPORTS? TELL US!

Current Valuations

    CADILA HEALTHCARE SANOFI INDIA CADILA HEALTHCARE/
SANOFI INDIA
 
P/E (TTM) x 29.8 44.0 67.6% View Chart
P/BV x 3.6 8.1 44.1% View Chart
Dividend Yield % 1.0 1.1 89.7%  

Financials

 CADILA HEALTHCARE   SANOFI INDIA
EQUITY SHARE DATA
    CADILA HEALTHCARE
Mar-19
SANOFI INDIA
Dec-18
CADILA HEALTHCARE/
SANOFI INDIA
5-Yr Chart
Click to enlarge
High Rs4326,840 6.3%   
Low Rs3064,630 6.6%   
Sales per share (Unadj.) Rs128.61,203.1 10.7%  
Earnings per share (Unadj.) Rs18.5165.3 11.2%  
Cash flow per share (Unadj.) Rs24.4209.9 11.6%  
Dividends per share (Unadj.) Rs3.5084.00 4.2%  
Dividend yield (eoy) %0.91.5 64.7%  
Book value per share (Unadj.) Rs101.5963.6 10.5%  
Shares outstanding (eoy) m1,023.7423.03 4,445.2%   
Bonus/Rights/Conversions ---  
Price / Sales ratio x2.94.8 60.3%   
Avg P/E ratio x19.934.7 57.4%  
P/CF ratio (eoy) x15.127.3 55.4%  
Price / Book Value ratio x3.66.0 61.2%  
Dividend payout %18.950.8 37.1%   
Avg Mkt Cap Rs m378,170132,078 286.3%   
No. of employees `00012.43.3 376.8%   
Total wages/salary Rs m21,2414,068 522.1%   
Avg. sales/employee Rs Th10,585.08,393.8 126.1%   
Avg. wages/employee Rs Th1,707.81,232.4 138.6%   
Avg. net profit/employee Rs Th1,526.51,153.0 132.4%   
INCOME DATA
Net Sales Rs m131,65627,708 475.2%  
Other income Rs m2,011897 224.2%   
Total revenues Rs m133,66728,605 467.3%   
Gross profit Rs m29,7316,235 476.8%  
Depreciation Rs m5,9861,027 582.9%   
Interest Rs m1,9357 27,642.9%   
Profit before tax Rs m23,8216,098 390.6%   
Minority Interest Rs m4690-   
Prior Period Items Rs m00-   
Extraordinary Inc (Exp) Rs m00-   
Tax Rs m5,3032,292 231.4%   
Profit after tax Rs m18,9873,806 498.9%  
Gross profit margin %22.622.5 100.4%  
Effective tax rate %22.337.6 59.2%   
Net profit margin %14.413.7 105.0%  
BALANCE SHEET DATA
Current assets Rs m84,98115,922 533.7%   
Current liabilities Rs m73,4256,235 1,177.6%   
Net working cap to sales %8.835.0 25.1%  
Current ratio x1.22.6 45.3%  
Inventory Days Days7564 117.1%  
Debtors Days Days11021 524.9%  
Net fixed assets Rs m133,4937,539 1,770.7%   
Share capital Rs m1,024230 445.2%   
"Free" reserves Rs m102,83921,962 468.3%   
Net worth Rs m103,86322,192 468.0%   
Long term debt Rs m39,4970-   
Total assets Rs m234,83129,839 787.0%  
Interest coverage x13.3872.1 1.5%   
Debt to equity ratio x0.40-  
Sales to assets ratio x0.60.9 60.4%   
Return on assets %8.912.8 69.7%  
Return on equity %18.317.2 106.6%  
Return on capital %18.327.5 66.5%  
Exports to sales %00-   
Imports to sales %00-   
Exports (fob) Rs mNANA-   
Imports (cif) Rs mNANA-   
Fx inflow Rs m48,4047,587 638.0%   
Fx outflow Rs m11,5937,145 162.3%   
Net fx Rs m36,811442 8,328.3%   
CASH FLOW
From Operations Rs m28,8233,739 770.9%  
From Investments Rs m-57,387-731 7,850.5%  
From Financial Activity Rs m18,846-1,972 -955.7%  
Net Cashflow Rs m-7,1051,036 -685.8%  

Share Holding

Indian Promoters % 74.8 0.0 -  
Foreign collaborators % 0.0 60.4 -  
Indian inst/Mut Fund % 8.3 14.4 57.6%  
FIIs % 5.9 14.6 40.4%  
ADR/GDR % 0.0 0.0 -  
Free float % 11.0 10.5 104.8%  
Shareholders   44,069 15,184 290.2%  
Pledged promoter(s) holding % 0.0 0.0 -  
NM: Not Meaningful
Source: Company Annual Reports, Regulatory Filings, Equitymaster

Compare CADILA HEALTHCARE With:   PFIZER  ABBOTT INDIA  PANACEA BIOTECH  WYETH LTD  GSK PHARMA  

Compare CADILA HEALTHCARE With:   MYLAN (US)  ACTAVIS (US)  ADCOCK INGRAM (S. Africa)  TEVA PHARMA (Israel)  



Today's Market

Sensex Ends 419 Points Higher; IT and Banking Stocks Witness Huge Buying(Closing)

Indian share markets continued their momentum and ended on a strong note today.

Related Views on News

SANOFI INDIA Announces Quarterly Results (4QFY20); Net Profit Down 8.1% (Quarterly Result Update)

May 21, 2020 | Updated on May 21, 2020

For the quarter ended March 2020, SANOFI INDIA has posted a net profit of Rs 854 m (down 8.1% YoY). Sales on the other hand came in at Rs 8 bn (up 9.4% YoY). Read on for a complete analysis of SANOFI INDIA's quarterly results.

CADILA HEALTHCARE Announces Quarterly Results (2QFY20); Net Profit Down 79.3% (Quarterly Result Update)

Nov 15, 2019 | Updated on Nov 15, 2019

For the quarter ended September 2019, CADILA HEALTHCARE has posted a net profit of Rs 829 m (down 79.3% YoY). Sales on the other hand came in at Rs 34 bn (up 13.7% YoY). Read on for a complete analysis of CADILA HEALTHCARE's quarterly results.

CADILA HEALTHCARE Announces Quarterly Results (1QFY20); Net Profit Down 28.9% (Quarterly Result Update)

Aug 13, 2019 | Updated on Aug 13, 2019

For the quarter ended June 2019, CADILA HEALTHCARE has posted a net profit of Rs 3 bn (down 28.9% YoY). Sales on the other hand came in at Rs 35 bn (up 20.8% YoY). Read on for a complete analysis of CADILA HEALTHCARE's quarterly results.

SANOFI INDIA Announces Quarterly Results (1QFY20); Net Profit Down 2.2% (Quarterly Result Update)

Jul 31, 2019 | Updated on Jul 31, 2019

For the quarter ended June 2019, SANOFI INDIA has posted a net profit of Rs 974 m (down 2.2% YoY). Sales on the other hand came in at Rs 7 bn (up 9.4% YoY). Read on for a complete analysis of SANOFI INDIA's quarterly results.

CADILA HEALTHCARE Announces Quarterly Results (4QFY19); Net Profit Down 21.0% (Quarterly Result Update)

May 30, 2019 | Updated on May 30, 2019

For the quarter ended March 2019, CADILA HEALTHCARE has posted a net profit of Rs 5 bn (down 21.0% YoY). Sales on the other hand came in at Rs 37 bn (up 14.8% YoY). Read on for a complete analysis of CADILA HEALTHCARE's quarterly results.

More Views on News

Most Popular

Smallcaps Are in a Sweet Spot Again: Are You Buying?(Profit Hunter)

Jul 3, 2020

This is why I believe smallcaps are the place to be in the near future.

How to Find the Best Stocks for Day Trading - 2(Fast Profits Daily)

Jul 10, 2020

Use this method to identify the right stocks to trade intraday.

How We Made 10%+ Profits Overnight(Fast Profits Daily)

Jul 3, 2020

A simple trade in natural gas delivered more than 10% overnight. Here's how we did it...

From a 57% Fall to Gains of 168%. This is What a Smallcap Rebound Really Looks Like(Profit Hunter)

Jul 7, 2020

This smallcap is essential enough to continue business even amid a second wave of infections, or lockdown.

More

India's #1 Trader
Reveals His Secrets

The Secret to Increasing Your Trading Profits Today
Get this Special Report, The Secret to Increasing Your Trading Profits Today, Now!
We will never sell or rent your email id.
Please read our Terms

CADILA HEALTHCARE SHARE PRICE


Jul 16, 2020 (Close)

TRACK CADILA HEALTHCARE

  • Track your investment in CADILA HEALTHCARE with Equitymaster's Portfolio Tracker. Set live price alerts, get research alerts and more. Get access now...
  • Add To MyStocks

MORE ON CADILA HEALTHCARE

CADILA HEALTHCARE 5-YR ANALYSIS

COMPARE CADILA HEALTHCARE WITH

MARKET STATS